Matthias Möller is responsible for marketing and product development at gogol medien. His first company in the field of print and online media, he founded in school already. Matthias Möller studied at LMU in Munich  and MIT in Cambridge and wrote his thesis at Harvard Business School. After graduation, he participated in building up the elite program Technology Management CDTM at the TUM and LMU and received his doctorate with Prof. Picot on innovation and product development. In parallel, he developed together with Vodafone, Siemens, BMW and Pro7 Sat1 for UMTS mobile services, and founded a company for the development of mobile communities. He also examines new challenges in sports, he is an avid climber, mountain climbers, skiers and alpine climbers.

About gogol medien:

gogol medien is a pioneer in cloud-based publishing systems for the publishing house business. The products are used by the major European publishers, such as WAZ, Madsack, Springer, Moser and Styria, enabling them to compete in the position to expand the rapidly changing media landscape.

More information about gogol medien can be found here. 

Frederik Lauterbach (34) is manager director of Luise Händlmaier Senffabrikation GmbH & Co KG in Regensburg. From 2003 to 2008 he was at Dr. Vielberth group in Regensburg (real estate investor) and was responsible for the areas of finance and project development. Frederik Lauterbach studied at LMU in Munich Business Administration with an emphasis on production management and controlling.

About Händlmaier Senffabrikation GmbH & Co KG:

Since 1914, the "Süße Hausmachersenf" ("Sweet Mustard") is sold (originally in-house butcher shop).The family company from Regensburg is currently in the 4th generation and is the nationwide leader in sweet mustard. In Germany, Händlmaier has a market share of 67%, in Bavaria, even over 78%. Since 2006 the product range was expanded steadily but selectively, to gourmet sauces, the brand "Wild African" and other variations of mustard. Currently signed the Food newspaper the New Innovation "squeeze-bottle" as the product of 2012.

More information about Händlmaier Senffabrikation can be found here. 

Benjamin Günther received his Business Administration degree majoring in marketing at the LMU in Munich. He also studied at UC Berkeley and in the fashion capital, Paris. He is CEO of STYLIGHT and responsible for marketing and business development.

About STYLIGHT:

The STYLIGHT GmbH, based in Munich, was founded in November 2008 by Anselm Bauer, Benjamin Günther, Max-Josef Meier und Sebastian Schuon. The company is supported by leading investors such as Holtzbrinck Ventures, Urs Keller and Stefan Gessulat. STYLIGHT uses specially developed algorithms from the image recognition to make fashion searchable in many shops. For their technology and business idea, the founder of STYLIGHT were honored with numerous awards, such as the European Tech Tour as one of the 25 "most promising startups Web".

More information about STYLIGHT can be found here.

Hendrik Brandis studied Technical Engineering at TUM, where he also received his doctorate. He is co-founder and partner of the Munich venture capital investor Earlybird, board member of EVCA and in several companies. Previously he was Chairman of the EVCA Venture Capital Platform Council. Dr. Brandis has 16 years experience as an investor and entrepreneur with a focus on web / cloud-enabled services and Telekom. Among his most successful exits include element 5 an Digital River (NASDAQ:DRIV); Dianoema (Mailand: NOE.MI) and dooyoo.de an Le Guide.com S.A..

About Earlybird:

Since its founding in 1997, Earlybird has invested in over 70 companies and achieved excellent results in international comparison. Currently manages the venture capital investor in more than 500 million € for more than 20 institutional investors.

More information about Earlybird can be found here.

Erich Schlick is one of a very few European scientists/drug developers to see their innovation become a blockbuster. This happened in the 1990s when he initiated the development of Humira, the first fully human therapeutic monoclonal antibody. Erich joined Wellington as an Investment Partner for Life Sciences in October 2005. Before this, he served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head 3i Healthcare Worldwide and was responsible for numerous successful investments.

Prior to venture capital, Erich spent 15 years with BASF Pharma Knoll AG, 10 years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D. During this time, he obtained worldwide registrations for five products in cardiovascular, metabolic and pain indications. In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira. Erich studied medicine and specialised in pharmacology. He holds a professorship of immunopharmacology at the University of Heidelberg/Mannheim.

About Wellington Partners:

Wellington Partners has been one of the most successful pan-European venture capital firms and a market leader in Germany for more than thirteen years. With funds totalling some € 800 million, we invest throughout Europe in companies that have the potential to become global technology and market leaders. Life Science has been one of our focus investment areas right from the beginning; today, we work with dedicated Life Sciences funds and a specialized investment team supporting companies in the fields of Medical Technology, Diagnostics, Therapeutics and Industrial Biotechnology.

More information about Wellington Partners can be found here.